Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV
about
ERCC2 2251A>C genetic polymorphism was highly correlated with early relapse in high-risk stage II and stage III colorectal cancer patients: a preliminary studyPharmacologic resistance in colorectal cancer: a reviewRandomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulationsS-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.Efficacy and short-term outcomes of preoperative chemoradiotherapy with intermittent oral tegafur-uracil plus leucovorin in Japanese rectal cancer patients: a single center experience retrospective analysis.Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.Colorectal cancer in Chinese patients: current and emerging treatment options.Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trialClinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancersEffect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthasePhase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer.Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancerJapanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer.Race does not explain genetic heterogeneity in pharmacogenomic pathways.S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysisML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer.A phase II study of preoperative chemoradiation with tegafur-uracil plus leucovorin for locally advanced rectal cancer with pharmacogenetic analysisCetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancerRecent advances in oral anticancer agents for colon cancer.Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies.Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off.Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients.Drug delivery of oral anti-cancer fluoropyrimidine agents.A multi-throughput multi-organ-on-a-chip system on a plate formatted pneumatic pressure-driven medium circulation platform.Cytotoxic T lymphocyte response to peptide vaccination predicts survival in stage III colorectal cancer.Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy.Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer.A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.Multicenter, phase II clinical trial of peptide vaccination with oral chemotherapy following curative resection for stage III colorectal cancer.
P2860
Q21260394-7AFCD6A1-5BEB-46E9-A697-DF6F790C7BB4Q26769850-BFB12397-32EB-4BE8-B958-097ED5DB37E6Q33417630-5EC4FD63-FCEB-4AA7-B853-AC44AA9307DDQ33426501-6108F704-97F5-45AA-9679-A15D9742120AQ33749847-BF481F4E-6A81-41E0-9EAA-195ADBD84E7FQ34165276-32D2FA45-5290-434D-91D5-4E7A18E87FDCQ34352595-53070825-CC6E-4027-A2EE-49ECF18CE973Q35859030-CBE48662-C3D8-4030-BB8D-FD07E5C71476Q35918752-1ABC4A26-B7A7-4A6B-A268-7EF8FAE0A6F8Q36142392-E6D7759A-5142-4DF4-ADF4-173EB2700B2CQ36230515-09688D3B-60AD-477D-9293-57E375396AF3Q36300533-CA55BB18-8267-4085-B2B3-72A9055D35A5Q36324953-F427A8E4-1257-4BE8-8461-8892C4B29BFDQ37076675-5F8BF9DB-3D9B-4B0A-8971-1D7D862EE5F6Q37182236-391DF6FE-D660-45AA-BFFA-3628F0A05082Q37642780-8D9C1776-3DBF-48A5-A97D-CE0E1427D296Q37724706-55C296B3-93AE-4330-B458-977891BD4CFAQ37735615-F226E670-57C2-43B6-82E8-15A92015833FQ38167885-0EEAEAF6-AC63-4440-874A-6E7E3689D071Q38707832-6C8D50E7-9D7C-42E9-BA03-976A78365E1FQ42288648-3979ECC2-222F-47C5-BDB1-EDA0236FCC59Q44217768-FA63E75E-CA6E-40D4-95DA-559736FDE29AQ48317852-43109F22-3C7F-483B-A221-B87934B76E8DQ49561409-5ECDF56E-E41D-4FC1-8668-F9BF2311CBB3Q50422213-82B1DF52-B885-4269-A96A-3470FC9DA290Q50998049-7E9DF53C-903A-4913-8078-2F7F153ABAC0Q53641063-EAD92DB5-6159-4BD6-B9AD-83EDD444D5F8Q53648255-5F6D56DA-302B-4D57-BDB1-932FBCC34580Q55013743-B94329A8-A7F3-4825-9860-FD4F9A88CC7D
P2860
Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Comparison of the efficacy, to ...... ates and Japan study of UFT/LV
@ast
Comparison of the efficacy, to ...... ates and Japan study of UFT/LV
@en
Comparison of the efficacy, to ...... ates and Japan study of UFT/LV
@nl
type
label
Comparison of the efficacy, to ...... ates and Japan study of UFT/LV
@ast
Comparison of the efficacy, to ...... ates and Japan study of UFT/LV
@en
Comparison of the efficacy, to ...... ates and Japan study of UFT/LV
@nl
prefLabel
Comparison of the efficacy, to ...... ates and Japan study of UFT/LV
@ast
Comparison of the efficacy, to ...... ates and Japan study of UFT/LV
@en
Comparison of the efficacy, to ...... ates and Japan study of UFT/LV
@nl
P2093
P921
P356
P1476
Comparison of the efficacy, to ...... ates and Japan study of UFT/LV
@en
P2093
F Nagashima
J L Abbruzzese
P J Loehrer
P J O'Dwyer
P304
P356
10.1200/JCO.2004.05.017
P407
P577
2004-09-01T00:00:00Z